Heidelberg Pharma AG

M&A Activity • Nov 17, 2010

News Details

Ad-hoc | 17 November 2010 22:27

WILEX AG acquires Oncogene Science assets from Siemens Healthcare Diagnostics

WILEX AG / Key word(s): Strategic Company Decision/Acquisition

17.11.2010 22:27

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)

WILEX acquires Oncogene Science assets from Siemens Healthcare Diagnostics

Munich, Germany, Cambridge, MA, USA; 17 November 2010: WILEX AG (ISIN
DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced the signing
of an agreement with Siemens Healthcare Diagnostics to acquire the assets
of Oncogene Science, a commercial business entity of Siemens Healthcare
Diagnostics, for approximately Euro 500,000 in cash. WILEX Inc., a wholly
owned newly founded US subsidiary of WILEX AG, will license patent rights,
acquire inventory including a stock of marketable diagnostic kits and will
also take over the fully equipped, state-of-the-art laboratory facilities
in Cambridge, MA. WILEX will also pay low-mid single digit royalties on the
sales of diagnostic kits to Siemens Healthcare Diagnostics.

WILEX Inc. will employ a team of 10 current Oncogene staff, including
scientists, experienced management and a sales team. The newly established
unit will focus exclusively on the manufacturing, marketing and sales of
diagnostic assays developed at Oncogene Science to existing and new
customers in the pharmaceutical and reference laboratory industries.

Oncogene Science is a specialist in the development, manufacturing and
commercialization of a variety of oncology biomarker assays with a specific
focus on measuring proteins in blood. The licensed IP portfolio includes
the only FDA cleared Serum HER-2/neu ELISA kit, CA IX patents covering CA
IX ELISA and IHC products, as well as a uPA diagnostics patent family,
which is complementary to the WILEX uPA therapeutic IP portfolio.
Diagnostic kits based on this patent portfolio are manufactured at
Oncogene's ISO registered manufacturing facilities in Cambridge, MA.
Siemens will retain automated platform rights for the Oncogene products,
including Serum HER-2/neu and CA IX.

Please find further information in the press release, especially details to
the conference calls.

Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors@wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

17.11.2010 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Berlin, Düsseldorf, Stuttgart

End of Announcement DGAP News-Service

---